Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Receives $35.75 Consensus Target Price from Analysts

Odyssey Therapeutics, Inc. (NASDAQ:ODTX) has been assigned a consensus recommendation of “Moderate Buy” from the eight brokerages that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $35.75.

A number of research analysts have recently issued reports on ODTX shares. Cantor Fitzgerald began coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They issued an “overweight” rating for the company. Weiss Ratings assumed coverage on shares of Odyssey Therapeutics in a report on Tuesday, August 11th. They issued a “sell (d+)” rating for the company. JPMorgan Chase & Co. boosted their target price on Odyssey Therapeutics from $26.00 to $29.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Wedbush began coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set an “outperform” rating and a $30.00 price target for the company. Finally, Zacks Research upgraded shares of Odyssey Therapeutics to a “hold” rating in a report on Wednesday, June 3rd.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Odyssey Therapeutics stock. The Manufacturers Life Insurance Company bought a new position in shares of Odyssey Therapeutics, Inc. (NASDAQ:ODTX) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 32,125 shares of the company’s stock, valued at approximately $601,000. The Manufacturers Life Insurance Company owned approximately 0.07% of Odyssey Therapeutics as of its most recent filing with the Securities & Exchange Commission.

Odyssey Therapeutics Trading Down 1.5%

ODTX opened at $24.26 on Thursday. The company has a market capitalization of $1.17 billion and a PE ratio of -3.58. Odyssey Therapeutics has a 1 year low of $15.10 and a 1 year high of $29.05. The company’s 50 day moving average price is $21.43.

Odyssey Therapeutics (NASDAQ:ODTX) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($1.74) EPS for the quarter. Analysts anticipate that Odyssey Therapeutics will post -5.99 earnings per share for the current year.

About Odyssey Therapeutics

Odyssey Therapeutics is a biotechnology company focused on discovering and developing precision medicines for immune-mediated diseases and cancer. The company combines computational biology, structural biology, medicinal chemistry and other drug-discovery technologies to identify therapies designed to target specific disease mechanisms.

Odyssey’s research programs are centered on small-molecule therapeutics intended to modulate immune pathways and address conditions with significant unmet medical needs.